Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism
ورودیهای بالینی بیمار
حداقل ۰.۰۱ — حداکثر ۱۰۰ • واحد: mIU/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- —1–1
- —2–2
- —3–3
- —4–4
The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include tsh miu l. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations
Clinical Indication
The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism is indicated for bedside clinical practice to support Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Can occur at any time during ICPi treatment, often irreversible.
Grading based on TSH levels (mIU/L), symptom severity, and presence of myxedema: Grade 1 (TSH <10, asymptomatic), Grade 2 (TSH >10 OR moderate symptoms with ADL preservation), Grade 3 (severe symptoms, unable to perform ADLs), Grade 4 (myxedema coma or life-threatening complications)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| tsh_miu_l | float | Yes | Thyroid-stimulating hormone (TSH) level in mIU/L(mIU/L) |
| symptom_severity | string | Yes | Patient symptom severity and functional status |
| myxedema_signs | string | Yes | Evidence of myxedema or life-threatening hypothyroid complications |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | — | Mild - Asymptomatic with TSH <10 mIU/L |
| 2–2 | — | Moderate - Moderate symptoms, able to perform ADLs, TSH >10 mIU/L |
| 3–3 | — | Severe - Severe symptoms, unable to perform ADLs |
| 4–4 | — | Life-threatening - Myxedema coma or life-threatening consequences |
Evidence-Based References (EBM)
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
- Faje AT, Sullivan R, Lawrence D, Trombetta M, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov;99(11):4078-85. doi: 10.1210/jc.2014-2306.DOI: 10.1210/jc.2014-2306
- Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min Y, Krop IE, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.DOI: 10.1001/jamaoncol.2017.3064
Related calculators
- Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus
- Immune-Related Adverse Events for GI Toxicity - Colitis
- Immune-Related Adverse Events for Lung Toxicity - Pneumonitis
- Immune-Related Adverse Events for GI Toxicity - Hepatitis
- Immune-Related Adverse Events for Renal Toxicities - Nephritis